320 related articles for article (PubMed ID: 17179232)
21. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
Pili R; Salumbides B; Zhao M; Altiok S; Qian D; Zwiebel J; Carducci MA; Rudek MA
Br J Cancer; 2012 Jan; 106(1):77-84. PubMed ID: 22134508
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
23. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
[TBL] [Abstract][Full Text] [Related]
24. First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors.
Brunetto AT; Ang JE; Lal R; Olmos D; Molife LR; Kristeleit R; Parker A; Casamayor I; Olaleye M; Mais A; Hauns B; Strobel V; Hentsch B; de Bono JS
Clin Cancer Res; 2013 Oct; 19(19):5494-504. PubMed ID: 24065624
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
Ngamphaiboon N; Dy GK; Ma WW; Zhao Y; Reungwetwattana T; DePaolo D; Ding Y; Brady W; Fetterly G; Adjei AA
Invest New Drugs; 2015 Feb; 33(1):225-32. PubMed ID: 25371323
[TBL] [Abstract][Full Text] [Related]
26. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
Aron JL; Parthun MR; Marcucci G; Kitada S; Mone AP; Davis ME; Shen T; Murphy T; Wickham J; Kanakry C; Lucas DM; Reed JC; Grever MR; Byrd JC
Blood; 2003 Jul; 102(2):652-8. PubMed ID: 12649137
[TBL] [Abstract][Full Text] [Related]
27. Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
Eyüpoglu IY; Hahnen E; Tränkle C; Savaskan NE; Siebzehnrübl FA; Buslei R; Lemke D; Wick W; Fahlbusch R; Blümcke I
Mol Cancer Ther; 2006 May; 5(5):1248-55. PubMed ID: 16731757
[TBL] [Abstract][Full Text] [Related]
28. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.
Wieduwilt MJ; Pawlowska N; Thomas S; Olin R; Logan AC; Damon LE; Martin T; Kang M; Sayre PH; Boyer W; Gaensler KML; Anderson K; Munster PN; Andreadis C
Clin Cancer Res; 2019 Aug; 25(16):4917-4923. PubMed ID: 31152020
[TBL] [Abstract][Full Text] [Related]
29. MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent.
Hess-Stumpp H; Bracker TU; Henderson D; Politz O
Int J Biochem Cell Biol; 2007; 39(7-8):1388-405. PubMed ID: 17383217
[TBL] [Abstract][Full Text] [Related]
30. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
[TBL] [Abstract][Full Text] [Related]
32. Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.
Camphausen K; Burgan W; Cerra M; Oswald KA; Trepel JB; Lee MJ; Tofilon PJ
Cancer Res; 2004 Jan; 64(1):316-21. PubMed ID: 14729640
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
[TBL] [Abstract][Full Text] [Related]
34. A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Batlevi CL; Crump M; Andreadis C; Rizzieri D; Assouline SE; Fox S; van der Jagt RHC; Copeland A; Potvin D; Chao R; Younes A
Br J Haematol; 2017 Aug; 178(3):434-441. PubMed ID: 28440559
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.
Gojo I; Perl A; Luger S; Baer MR; Norsworthy KJ; Bauer KS; Tidwell M; Fleckinger S; Carroll M; Sausville EA
Invest New Drugs; 2013 Oct; 31(5):1217-27. PubMed ID: 23443507
[TBL] [Abstract][Full Text] [Related]
36. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
Byrd JC; Marcucci G; Parthun MR; Xiao JJ; Klisovic RB; Moran M; Lin TS; Liu S; Sklenar AR; Davis ME; Lucas DM; Fischer B; Shank R; Tejaswi SL; Binkley P; Wright J; Chan KK; Grever MR
Blood; 2005 Feb; 105(3):959-67. PubMed ID: 15466934
[TBL] [Abstract][Full Text] [Related]
37. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases.
Simonini MV; Camargo LM; Dong E; Maloku E; Veldic M; Costa E; Guidotti A
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1587-92. PubMed ID: 16432198
[TBL] [Abstract][Full Text] [Related]
38. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Saito A; Yamashita T; Mariko Y; Nosaka Y; Tsuchiya K; Ando T; Suzuki T; Tsuruo T; Nakanishi O
Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4592-7. PubMed ID: 10200307
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
40. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
